Trial Profile

BRE-03: Window of Opportunity Trial of Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms BRE-03

Most Recent Events

28 Aug 2026 Planned End Date changed from 1 Jul 2026 to 1 Jul 2027.
28 Aug 2026 Planned primary completion date changed from 1 Jul 2026 to 1 Jul 2027.
28 Aug 2026 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com